---

Highlights of March 2021

1. Sun Pharma subsidiary to acquire 12.5% stake in WRS Bioproducts Australia.
2. Piramal Pharma to buy 100% stake in Hemmo Pharmaceuticals for Rs.775 crore (~US$106 Million).
3. Glenmark and Bausch Health join together to commercialize RYALTRIS ™ nasal spray in Canada.
4. Russia’s RDIF partners with Stelis India to supply 200 million doses of the Sputnik V vaccine.
5. Lupin Announces Partnership with Endoceutics for the commercialization of Intrarosa.
6. Cipla Ltd’s US specialty business division has entered into an agreement with US-based SIGA Technologies Inc to develop novel antibiotics.
7. Gland Pharma inks pact to supply 252 Million doses of Sputnik V Covid vaccine.
8. Jubilant Radiopharma and Isotopia Molecular Imaging Enter into a Strategic Partnership to Further Advance the Field of Radiotherapeutics.
9. Taiwan and US based Foresee Pharmaceuticals has entered into an exclusive license agreement with Indian firm Intas Pharmaceuticals for the US commercialization of Foresee's novel FP-001 program.
10. Cipla Gulf FZ LLC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia and New Zealand.
11. Dr Reddy’s Laboratories, Cipla Join Hands to Invest in ABCD Technologies.
12. Agilent to pick up cancer blood tester Resolution Bio in US$695 Million deal.
13. Genevant nabs US$600 Million deal with Japan’s Takeda.
14. AstraZeneca inks new US$205 Million deal with US govt for COVID-19 antibody AZD7442.
15. Pharmaron acquires UK biomanufacturing site from AbbVie.

Highlights at Aagami: 

1. Large Pharma acquires stake in Aagami’s Australian client.
2. Japanese BioPharma appoints Aagami for US partnering of their NDA filed asset for Postherpetic neuralgia.
3. Aagami Participated in Bio Europe Spring 2021 with great success and to attend ChinaBio, BIO International, Bio Pharm America and Bio-Europe 2021 partnering conferences in 2021.